KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Dividends Paid - Common (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Dividends Paid - Common for 7 consecutive years, with $40.8 million as the latest value for Q4 2025.

  • Quarterly Dividends Paid - Common rose 29.6% to $40.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $167.5 million through Dec 2025, up 33.81% year-over-year, with the annual reading at $167.5 million for FY2025, 33.81% up from the prior year.
  • Dividends Paid - Common hit $40.8 million in Q4 2025 for Royalty Pharma, up from $34.3 million in the prior quarter.
  • In the past five years, Dividends Paid - Common ranged from a high of $125.7 million in Q1 2021 to a low of -$230.2 million in Q4 2021.
  • Historically, Dividends Paid - Common has averaged $34.5 million across 5 years, with a median of $33.8 million in 2023.
  • Biggest YoY gain for Dividends Paid - Common was 114.4% in 2022; the steepest drop was 72.55% in 2022.
  • Year by year, Dividends Paid - Common stood at -$230.2 million in 2021, then soared by 114.4% to $33.2 million in 2022, then dropped by 26.13% to $24.5 million in 2023, then rose by 28.42% to $31.4 million in 2024, then grew by 29.6% to $40.8 million in 2025.
  • Business Quant data shows Dividends Paid - Common for RPRX at $40.8 million in Q4 2025, $34.3 million in Q3 2025, and $38.6 million in Q2 2025.